Our ambition is to position DESTINA Genomics Ltd as a market leader and innovator in the rapidly evolving field of molecular diagnostics. We envision a world where routine use of RNA biomarkers is a reality, and we are at the forefront of making it possible.

We expect our technology to seamlessly integrate with existing detection platforms to enable earlier and more accurate disease detection, thereby contributing to improved patient outcomes. With a keen eye on market trends, the company is poised to make meaningful progress in his RNA therapeutics and CRISPR markets.

We are always committed to innovation, collaboration and the pursuit of excellence. We are DESTINA – we are part of the future of molecular diagnostics.

At Destina Genomics, S.L., we believe that quality is not a one-time goal, but a way of working. For this reason, we have made a firm commitment to quality, initiating the development of a Quality Management System based on the ISO 9001 standard as a first step towards excellence and continuous improvement, with the purpose of achieving certification of our system by the end of 2026.

This commitment is reflected in the ongoing optimization of our processes, the strengthening of customer satisfaction, and the consolidation of an organizational culture focused on efficiency, transparency, and trust.

In the medium term, we also plan to move towards the implementation of the ISO 13485 standard, further reinforcing our commitment to international standards that ensure the safety, reliability, and quality of our products and services.